3SBio Inc - Company Profile
Powered by 
All the sales intelligence you need on 3SBio Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how 3SBio Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with 3SBio Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
3SBio Inc (3SBio) is a biotechnology company that discovers, develops, manufactures, and markets biopharmaceutical products. Its major products include TPIAO for the treatment of chemotherapy-induced Thrombocytopenia (CIT), immune thrombocytopenia (ITP), and chronic liver disease-related thrombocytopenia (CLDT); EPIAO to treat anemia associated with chronic kidney disease, chemotherapy-induced anemia (CIA), and the reduction of allogeneic blood transfusion in surgery patients; Yisaipu to treat ankylosing spondylitis (AS) and psoriasis; Cipterbin to treat HER2-positive metastatic breast cancer in combination with chemotherapy; and Mandi to treat androgenetic alopecia (AGA) and alopecia areata. The company also offers contract development and manufacturing operations through its subsidiaries. 3SBio provides its products to hospitals and medical institutions. The company operates manufacturing bases in China and Italy. 3SBio is headquartered in Shenyang, Liaoning, China.
Headquarters
China
Address
Cricket Square Hutchins Drive, P. O. Box 2681, Grand Cayman, Shenyang, Liaoning , KY1-1111
Website
www.3sbio.com
Telephone
86 242 5386000
No of Employees
6,109
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1530 (HKG)
Revenue (2024)
$2.5B
94.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
305.8%
(2024 vs 2023)
Market Cap*
$5.5B
Net Profit Margin (2024)
XYZ
108.9%
(2024 vs 2023)
* As of and is in US$
3SBio Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| TPIAO - Chemotherapy-Induced Thrombocytopenia, Immune Thrombocytopenia, Pediatric Immune Thrombocytopenia, and Chronic Liver Disease-Related Thrombocytopenia | Contract Development and Manufacturing Services (CDMO) | TPIAO |
| EPIAO - Chronic Kidney Disease Anemia, Chemotherapy-Induced Anemia, and Reduction Of Allogeneic Blood Transfusion In Surgery Patients | EPIAO | |
| SEPO - Anemia | SEPO | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In May, the company signed a global, ex-China, licensing agreement with Pfizer to promote manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. |
| 2025 | Contracts/Agreements | In February, the company entered into a strategic cooperation agreement with Sichuan Baili Tianheng Pharmaceutical Co Ltd to collaboratively advance the use of the combination of 707 and BL-B01D1 for the treatment of solid tumors in mainland China. |
| 2025 | Contracts/Agreements | In January, Shenyang Sunshine Pharmaceutical Co., Ltd. entered into an agreement with Duality Biologics (Shanghai) Co., Ltd. to commercialize HER2 ADC drug DB-1303 for multiple indications in China, Hong Kong and Macau. |
Competitor Comparison
| Key Parameters | 3SBio Inc | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | Innovent Biologics Inc | Kexing Biopharm Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shenyang | Shanghai | Lianyungang | Suzhou | Jinan |
| State/Province | Liaoning | Shanghai | Jiangsu | Jiangsu | Shandong |
| No. of Employees | 6,109 | 40,603 | 20,602 | 7,502 | 1,048 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lou Jing | President; Chairman; Chief Executive Officer | Executive Board | 2014 | 63 |
| He Xiang | Chief Financial Officer | Senior Management | 2023 | 42 |
| Su Dongmei | Executive Director; Senior Vice President | Executive Board | 2014 | 56 |
| Liu Yanli | Director; General Manager - Sunshine Guojian | Senior Management | 2023 | 45 |
| Lai Siu Kuen | Company Secretary | Senior Management | 2022 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer